EQS-News

PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International 20.02.2026, 09:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: PL BioScience GmbH / Key word(s): Agreement
PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International

20.02.2026 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International

  • Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market.
  • The agreement marks PL BioScience’s first exclusive distribution partnership in Japan.
  • Cell culture media market in Japan expected to grow in the low-to-mid double digits annually, with typical projected averages around 12–14 % over the next decade as demand expands in research, biopharmaceuticals, and regenerative medicine.

Aachen, Germany, 20 February 2026 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL), today announced an exclusive distribution agreement for the Japanese market with Summit Pharmaceuticals International Corporation (SPI) to support local availability of ELAREM™ Ultimate-FD PLUS (GMP Grade) and the broader ELAREM™ platform for clinical applications. Through this partnership, customers in Japan will have a dedicated expert for product supply ordering, commercial support, procurement streamlining and faster adoption of qualified raw materials in early-stage development.

SPI is a wholly owned group company of Sumitomo Corporation, one of the largest worldwide general trading companies listed on the Tokyo Stock Exchange Prime Market. It links pharmaceutical companies globally, offering bioresources, licensing, manufacturing support, and more.

“We are excited to team up with SPI as this distribution agreement lays the groundwork for PL BioScience’s expansion into the Japanese market”, said Jungsoo Park, VP of Marketing and Sales, PL BioScience. “We believe there is a strong alignment between the two companies and shared values of high-quality products and customer support.”

 

About ELAREM Ultimate-FD PLUS (GMP Grade):

ELAREM™ Ultimate-FD PLUS is a gamma irradiated, fibrinogen-depleted and anticoagulant-free Human Platelet Lysate of EU origin. As a xeno-free cell culture supplement, the product supports the efficient and safe in vitro expansion of primary cells and cell lines. The product is especially suited to cell manufacturing applications requiring proven viral reduction, e.g. for potential use in clinical trials. It is manufactured, tested and released in compliance with the relevant GMP guidelines. The manufacturing process for the product is patented.

About PL BioScience:

PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The company has pioneered proprietary technology to produce fully artificial HPL, allowing for a fully lab-made, scalable supply of HPL. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications – the ELAREM™ platform. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. PL BioScience is the only company worldwide holding a patent for the gamma-irradiation of HPL, covering the manufacturing process for ELAREM™ Ultimate-FD PLUS.

For more information on PL BioScience and the ELAREM™ platform, visit: https://www.pl-bioscience.com/

About Summit Pharmaceuticals International:

Summit Pharmaceutical International Corporation (SPI), headquartered in Tokyo, Japan, is a leading specialized trading company, serving as the core trading arm of the Sumitomo Corporation Group’s pharmaceutical business. SPI provides a comprehensive range of services across the entire pharmaceutical value chain, including the sourcing of cutting-edge biotechnology and raw materials, licensing mediation for drug discovery and development, and the manufacturing and marketing of pharmaceuticals. By leveraging its global network and scientific expertise in related areas, SPI is dedicated to bridging the pharmaceutical-related companies in Japan and overseas companies, enhancing global health and well-being.

Website: https://www.summitpharma.co.jp/english/

 

Contact:
Dr. Hatim Hemeda, CEO
PL BioScience GmbH
+49(0)24195719-100
info@pl-bioscience.com

 

Media contact for PL BioScience:
MC Services AG
EU : Raimund Gabriel, Dr. Regina Lutz
+49 (0)89 210 228 0 

U.S.: Catherine Featherston
+1-203-444-4393
E-Mail: plbioscience@mc-services.eu

 

For high-resolution images, please contact plbioscience@mc-services.eu



20.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: PL BioScience GmbH
Auf der Hüls 184-186
52068 Aachen
Germany
E-mail: info@pl-bioscience.com
Internet: www.pl-bioscience.com
EQS News ID: 2278944

 
End of News EQS News Service

2278944  20.02.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
News-Kommentare
Thema
1 BYD investiert Milliarden: Europa-Offensive startet jetzt Hauptdiskussion
2 Biontech kehrt zu seinen Wurzeln zurück Hauptdiskussion
3 Trump: Geplanter Angriff auf Iran gestoppt Hauptdiskussion
4 ROUNDUP 2/Trump droht: 'Für den Iran tickt die Uhr' Hauptdiskussion
5 Taiwans Präsident bangt um Sicherheitsversprechen der USA Hauptdiskussion
6 ROUNDUP/Trump droht: 'Für den Iran tickt die Uhr' Hauptdiskussion
7 Tesla-Absturz: Musk wie immer mit neuen Ankündigungen Hauptdiskussion
Alle Diskussionen
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer